Literature DB >> 8452582

The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis.

I M Clark1, L K Powell, S Ramsey, B L Hazleman, T E Cawston.   

Abstract

OBJECTIVE: To compare the levels of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluid (SF) from patients with rheumatoid arthritis (RA) and patients with osteoarthritis (OA). This study aims to clarify existing data from previously used enzyme or inhibitor activity assays performed following separation by gel filtration, by using a 1-step enzyme-linked immunosorbent assay (ELISA) for each component.
METHODS: Total collagenase, free TIMP, and collagenase-TIMP complex were measured using a newly developed, specific double-antibody sandwich ELISA:
RESULTS: Levels of both collagenase and TIMP were significantly higher in RA patients (collagenase 1,560 +/- 150 ng/ml [mean +/- SEM], TIMP 1,610 +/- 130 ng/ml; n = 80) than OA patients (collagenase 420 +/- 90 ng/ml, TIMP 1,050 +/- 60 ng/ml; n = 80), with the difference being especially striking for collagenase. Sixteen RA fluids had detectable levels of collagenase-TIMP complex, compared with only 3 OA fluids.
CONCLUSION: The level of total collagenase in SF is greater in RA than OA, while levels of free TIMP show more overlap between the 2 diseases; this may simply reflect the increased inflammation seen in RA, or it may reflect a different disease mechanism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452582     DOI: 10.1002/art.1780360313

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  32 in total

1.  Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis.

Authors:  A Stallmach; C C Chan; K W Ecker; G Feifel; H Herbst; D Schuppan; M Zeitz
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

2.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.

Authors:  Y Yoshihara; H Nakamura; K Obata; H Yamada; T Hayakawa; K Fujikawa; Y Okada
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

3.  The matrix metalloproteinase inhibitor BB-1101 prevents experimental autoimmune uveoretinitis (EAU).

Authors:  G R Wallace; R A Whiston; M R Stanford; G M Wells; A J Gearing; J M Clements
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 4.  Are fibroblasts involved in joint destruction?

Authors:  T Pap; I Meinecke; U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

5.  Measurement of activity of collagenolytic MMP and inhibitors of MMPs using radiolabeled collagen substrate.

Authors:  Tim E Cawston
Journal:  Nat Protoc       Date:  2009-02-12       Impact factor: 13.491

6.  An aggrecan-degrading activity associated with chondrocyte membranes.

Authors:  C J Billington; I M Clark; T E Cawston
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

7.  Inhibitory effect of cephalothin on matrix metalloproteinase activity around loose hip prostheses.

Authors:  S Santavirta; M Takagi; Y T Konttinen; T Sorsa; A Suda
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

8.  Interleukin 13 blocks the release of collagen from bovine nasal cartilage treated with proinflammatory cytokines.

Authors:  C S Cleaver; A D Rowan; T E Cawston
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

9.  Comparison of modern marker proteins in serum and synovial fluid in patients with advanced osteoarthrosis and rheumatoid arthritis.

Authors:  S Andereya; N Streich; B Schmidt-Rohlfing; T Mumme; R Müller-Rath; U Schneider
Journal:  Rheumatol Int       Date:  2005-07-06       Impact factor: 2.631

10.  Resistance of small leucine-rich repeat proteoglycans to proteolytic degradation during interleukin-1-stimulated cartilage catabolism.

Authors:  R Sztrolovics; R J White; A R Poole; J S Mort; P J Roughley
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.